FDANews
www.fdanews.com/articles/85436-valeant-s-viramidine-fails-to-meet-efficacy-goal-in-treating-hepatitis-c

VALEANT'S VIRAMIDINE FAILS TO MEET EFFICACY GOAL IN TREATING HEPATITIS C

March 21, 2006

Valeant Pharmaceuticals has announced that the overall response rate for its drug Viramidine in treating hepatitis C was lower than expected, although the safety profile of the drug was superior to the standard drug ribavirin.

Viramidine (taribavirin hydrochloride) is a nucleoside analog prodrug of Ribavirin, in oral form, for administration in combination with a pegylated interferon for the treatment of chronic hepatitis C.